Algert Global’s Foghorn Therapeutics FHTX Stock Holding History

Algert Global’s Portfolio FHTX Stock Details FHTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-13,928	Closed	-$66.6K	–	1303
2026 Q1	$66.6K	Hold	13,928	–	–	﹤0.01%	1123
2025 Q4	$75.2K	Buy	+13,928	New	+$63.1K	﹤0.01%	1104

Other funds holding FHTX

Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return

Euclidean Capital New York $440M AUM 28.33% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Algert Global's FHTX Position: Q2 2026 in Review

Algert Global sold out of Foghorn Therapeutics (FHTX) in Q2 2026, closing a stake of 13,928 shares — an estimated $66.6K sold.

Algert Global first reported a position in FHTX in Q4 2025 and held it in 2 quarters. The position peaked at $75.2K in Q4 2025. 103 funds tracked by Wall St. Rank hold FHTX as of Q2 2026.

Algert Global reported no remaining Foghorn Therapeutics position as of Q2 2026 after selling out during the quarter.
Algert Global sold 13,928 Foghorn Therapeutics shares in Q2 2026, an estimated $66.6K.
Algert Global first reported a position in Foghorn Therapeutics in Q4 2025 and held it in 2 quarters.
Algert Global's Foghorn Therapeutics position peaked at $75.2K in Q4 2025.
103 funds tracked by Wall St. Rank held Foghorn Therapeutics as of Q2 2026.

Based on Algert Global's 13F filing for Q2 2026, filed 13 Aug 2026.